関連する実験動画
Updated: Jun 29, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
パッシブ心室制約は,左心室改造におけるトランムラル・シーア・ストレスの進行を防ぐ
Allen Cheng1, Tom C Nguyen, Marcin Malinowski
1Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, California 94305-5247, USA.
Circulation
|July 6, 2006
まとめ
Acorn Cardiac Support Device (CSD) は,心筋梗塞 (MI) の後の左心室 (LV) の不良改造を防止する. CSDはシアストレスの異常を軽減し,LVの膨張を防止し,壁のストレスを軽減します.
科学分野:
- 心血管科学の研究について
- バイオメディカルエンジニアリング
- 心臓のメカニズム 心臓のメカニズム
背景:
- パッシブ心室制約は,左心室 (LV) 壁のストレスと心筋の伸縮を軽減し,LVの改造の重要な要因です.
- 変化した壁のストレンは,アポトーシス,細胞外マトリックス破壊,有害なLV膨張を引き起こす可能性があります.
- Acorn Cardiac Support Device (CSD) の地域性トランスムラルLV壁株への影響は,以前は知られていなかった.
研究 の 目的:
- 心筋梗塞 (MI) の後の地域性トランムラルLV壁株に対するAcorn心臓サポート装置 (CSD) の影響を調査する.
- CSDの有害なLVリモデリングと心臓のメカニズムの変化を予防する効果を評価する.
主な方法:
- 33頭の羊は,4Dマーカーのダイナミクス測定のために,放射線不透明のビーズセットをLV壁に外科的に挿入した.
- 18頭の羊に心筋梗塞 (MI) が誘発され,8頭の羊は心筋梗塞 (MI+CSD) を受け,10頭の羊は心筋梗塞 (MI) を受けなかった.
- バイプレンのビデオ・フローロスコーピーは,1週目と8週間のMI後の1週目と8週間のLV容量,球性指数,およびトランムラル・シストリック株を分析し,マーカーダイナミクスを追跡しました.
主要な成果:
- MIは,Sham.と比較して,LVの拡張,球体性指数の減少,および前面と横面の両方の壁の縦横半径切断の増加をもたらしました.
- MI+CSDの羊にCSDを植え付けることで,これらのシアストレスの異常を防ぐことができました.
- CSDは,LVの末期ダイアストリック体積増加を最小限に抑え,LV球性指数を増加させた.
結論:
- 予防的なCSDは,心臓発作が誘発した,心臓発作ゾーンに隣接し,または遠隔の,シーザーストレスの進行を効果的に防止しました.
- CSDは,心筋梗塞後のLVの膨張と球化を予防する能力を実証しました.
- シーアストレスの異常を弱めることで,CSDはLVリフォームのポジティブフィードバックループを中断し,有害な心臓リフォームのトリガーを減らすことができます.
関連する概念動画
Chambers of the Heart
The human heart is a complex organ made up of four chambers: the right and left atria and the right and left ventricles. These internal chambers are separated by partitions known as the interatrial and interventricular septa. The exterior of the heart features a groove known as the coronary sulcus that demarcates the atria from the ventricles, while the anterior and posterior interventricular sulci distinguish between the two ventricles.
Deoxygenated blood from the body is received in the right...
Deoxygenated blood from the body is received in the right...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

